Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Gastric Cancer With HER2-overexpression

NCT04714190 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT04714190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04714190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Gastric Cancer With HER2-overexpression
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
March 24, 2021
Completion date
June 30, 2025
Enrollment
351 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, her2 overexpressing gastric carcinoma